Helen I. Torley

2021

In 2021, Helen I. Torley earned a total compensation of $7.5M as President and Chief Executive Officer at Halozyme Therapeutics, a 14% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$807,619
Option Awards$1,740,001
Salary$830,221
Stock Awards$4,060,081
Other$15,372
Total$7,453,294

Torley received $4.1M in stock awards, accounting for 54% of the total pay in 2021.

Torley also received $807.6K in non-equity incentive plan, $1.7M in option awards, $830.2K in salary and $15.4K in other compensation.

Rankings

In 2021, Helen I. Torley's compensation ranked 1,593rd out of 12,415 executives tracked by ExecPay. In other words, Torley earned more than 87.2% of executives.

ClassificationRankingPercentile
All
1,593
out of 12,415
87th
Division
Manufacturing
580
out of 5,505
90th
Major group
Chemicals And Allied Products
215
out of 2,375
91st
Industry group
Drugs
180
out of 2,096
91st
Industry
Biological Products, Except Diagnostic Substances
50
out of 449
89th

Pay ratio

Helen I. Torley's Pay$7,453,294
Median Employee's Pay$291,734
Pay Ratio

26

to 1

In 2021, the annual total compensation of Helen I. Torley was $7,453,294.

The annual total compensation of the median employee at Halozyme Therapeutics was $291,734.

The ratio of Helen I. Torley's pay to the pay of median employee was therefore 26 to one.

Source: SEC filing on March 25, 2022.

Torley's colleagues

We found three more compensation records of executives who worked with Helen I. Torley at Halozyme Therapeutics in 2021.

2021

Masaru Matsuda

Halozyme Therapeutics

General Counsel

2021

Michael LaBarre

Halozyme Therapeutics

Senior Vice President, Chief Technical Officer

2021

Elaine Sun

Halozyme Therapeutics

Chief Financial Officer

News

You may also like